Sanofi ADS (SNY)
Stock · NASDAQ · Health Care
$40.61as of 10/16/2026
Price chart
Active signals
SNY Signal Track Record
How signals performed across all stocks →What SNY's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -0.3% | 46% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 30 | -1.9% | 30% | August 17, 2026 |
| Bollinger Band Breakdown | 22 | +1.9% | 59% | September 24, 2026 |
| Bollinger Band Breakout | 23 | +0.7% | 52% | August 19, 2026 |
| Any 20-session window (baseline) | +0.2% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 74,846
- Website
- www.sanofi.com/
Fundamentals
- 1-day range
- $40.16$40.61
- Market cap
- $104.60B
- P/E (trailing)
- 21.77
- P/E (forward)
- 7.69
- EPS (trailing)
- $3.26
- Dividend yield
- 4.12%
- Beta
- 0.58
- Avg. volume
- 2.98M
- Ex-dividend date
- May 4, 2026
- Dividend pay date
- June 3, 2026
Forecasts
9 analyst ratings
Sanofi ADS Competitors
Chosen by industry and closest market cap.
- SNYSanofi ADS$40.61▲ 0.79%Market cap $104.60BP/E 21.77$69.75$91.15
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$49.51▲ 1.00%Market cap $105.65BP/E 15.09$1,592$2,282
- VRTXVertex Pharmaceuticals Incorporated Common Stock$499.74▼ 1.77%Market cap $122.68BP/E 29.32$403.16$560.25
- REGNRegeneron Pharmaceuticals Inc. Common Stock$790.74▼ 0.70%Market cap $79.49BP/E 19.00$564$859.34
- BMYBristol-Myers Squibb Company Common Stock$59.75▼ 1.35%Market cap $131.04BP/E 13.53$42.52$68.64
- PFEPfizer Inc. Common Stock$29.58▲ 0.48%Market cap $149.33BP/E 39.08$23.62$29.49
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$19.67▲ 1.13%Market cap $53.78BP/E —$4,102$6,183
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SNY Sanofi ADS | $104.60B | 21.77 | $40.61 | ▲ 0.79% | $69.75$91.15 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.09 | $49.51 | ▲ 1.00% | $1,592$2,282 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 29.32 | $499.74 | ▼ 1.77% | $403.16$560.25 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 19.00 | $790.74 | ▼ 0.70% | $564$859.34 |
| BMY Bristol-Myers Squibb Company Common Stock | $131.04B | 13.53 | $59.75 | ▼ 1.35% | $42.52$68.64 |
| PFE Pfizer Inc. Common Stock | $149.33B | 39.08 | $29.58 | ▲ 0.48% | $23.62$29.49 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $19.67 | ▲ 1.13% | $4,102$6,183 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Recursion Pharmaceuticals (RXRX) Stock is Trending After Hours: Here’s What You Should Knowbenzinga · 10/16/2026
- 5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% Plus (October 2026)SeekingAlpha · 10/10/2026
- Teva: 'Hold' On FDA Approval Of Weltruza And Pivot To Growth StrategySeekingAlpha · 10/9/2026
- Vallourec (ENXTPA:VK) Names A New Digital Chief, Is It Still 32% Below Fair Value?Yahoo · 10/8/2026
- Pharma’s $500B patent problem will come in waves — not as a cliffYahoo · 10/8/2026
- Veeva Summit to Showcase AI Innovations and the Leaders Transforming R&D and QualityYahoo · 10/8/2026
- European Equities Traded in US as ADRs Fall in Wednesday TradingYahoo · 10/7/2026
- Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MMYahoo · 10/7/2026
- Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)Yahoo · 10/6/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 206.95M
- Total value held
- $9.69B
- Institutional holders
- 736
- Unknown29.50M
- Unknown12.51M
- Unknown11.44M
- Unknown9.48M
- Unknown7.17M
- Unknown6.62M
- Unknown5.89M
- Unknown5.04M
- Unknown4.75M
- Unknown4.01M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Sanofi Advances AI Drug Collaboration With Recursion
Sanofi has launched a new drug collaboration with Recursion Pharmaceuticals, a move that sent Recursion's shares soaring. This partnership adds an AI-driven immunology candidate to Sanofi's pipeline, prompting analysts to reassess the company's fair value. While the stock currently trades well below its 52-week high, the new deal provides fresh context for investors evaluating the company's long-term growth potential.
Sanofi Advances AI Drug Collaboration With Recursion. Sanofi has launched a new drug collaboration with Recursion Pharmaceuticals, a move that sent Recursion's shares soaring. This partnership adds an AI-driven immunology candidate to Sanofi's pipeline, prompting analysts to reassess the company's fair value. While the stock currently trades well below its 52-week high, the new deal provides fresh context for investors evaluating the company's long-term growth potential.